Our Publications

Publications

Belle, K., Shabazz, F. S., Nuytemans, K., Davis, D. A., Ali, A., Young, J. L., … & Dykxhoorn, D. M. (2017).Generation of disease-specific autopsy-confirmed iPSCs lines from postmortem isolated Peripheral Blood Mononuclear Cells. Neuroscience Letters, 637, 201-206.

Deng, H. X., Shi, Y., Yang, Y., Ahmeti, K. B., Miller, N., Huang, C., … & Corbett, N. J. (2016). Identification of TMEM230 mutations in familial Parkinson’s disease. Nature genetics.

Xiong N, Li N, Martin E, Yu J, Li J, Liu J, Lee DY, Isacson O, Vance J, Qing H, Wang T, Lin Z. (2016). hVMAT2: A target of Individualized Medication for Parkinson’s Disease. Neurotherapeutics.

Nuytemans, K., Maldonado, L., Ali, A., John-Williams, K., Beecham, G. W., Martin, E., … & Vance, J. M. (2016). Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. Neurology Genetics, 2(1), e44.

Wang, X., Li, N., Xiong, N., You, Q., Li, J., Yu, J., … & Vance, J. M. (2016). Genetic variants of microtubule actin cross-linking factor 1 (MACF1) confer risk for Parkinson’s disease. Molecular neurobiology, 1-11.

Wang, L., Maldonado, L., Beecham, G. W., Martin, E. R., Evatt, M. L., Ritchie, J. C., … & Vance, J. M. (2016). DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurology Genetics, 2(3), e72.

Wang, L., Evatt, M. L., Maldonado, L. G., Perry, W. R., Ritchie, J. C., Beecham, G. W., … & Scott, W. K. (2015). Vitamin D from different sources is inversely associated with Parkinson disease. Movement Disorders, 30(4), 560-566.

Sharp, M. E., Caccappolo, E., Mejia‐Santana, H., Tang, M. X., Rosado, L., Orbe Reilly, M., … & Bressman, S. (2015). The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study. Movement Disorders, 30(2), 278-283.

Nalls, M. A., Bras, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E., … & Plagnol, V. (2015). NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of aging, 36(3), 1605-e7.

Beecham, G. W., Dickson, D. W., Scott, W. K., Martin, E. R., Schellenberg, G., Nuytemans, K., … & Hurtig, H. I. (2015). PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology,84(10), 972-980.

Wang, L., Evatt, M. L., Maldonado, L. G., Perry, W. R., Ritchie, J. C., Beecham, G. W., … & Scott, W. K. (2015). Vitamin D from different sources is inversely associated with Parkinson disease. Movement Disorders, 30(4), 560-566.

Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M. X., Rosado, L., Reilly, M. O., … & Bressman, S. B. (2014). Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA neurology,71(1), 62-67.

Hamza, T. H., Hill-Burns, E. M., Scott, W. K., Vance, J. M., Factor, S. A., Zabetian, C. P., & Payami, H. (2014). Glutamate receptor gene GRIN2A, coffee, and Parkinson disease. PLoS Genet, 10(11), e1004774.

Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., … & Schulte, C. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nature genetics, 46(9), 989-993.

Nuytemans, K., Inchausti, V., Beecham, G. W., Wang, L., Dickson, D. W., Trojanowski, J. Q., … & Honig, L. S. (2014). Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson’s disease. Movement Disorders, 29(6), 827-830.

Nuytemans, K., Bademci, G., Kohli, M. M., Beecham, G. W., Wang, L., Young, J. I., … & Haines, J. L. (2013). C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Annals of human genetics, 77(5), 351-363.

Pichler, I., Fabiola Del Greco, M., Gögele, M., Lill, C. M., Bertram, L., Do, C. B., … & Keller, M. F. (2013).Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. PLoS Med, 10(6), e1001462.

Wang, L., Nuytemans, K., Bademci, G., Jauregui, C., Martin, E. R., Scott, W. K., … & Zuchner, S. (2013). High‐Resolution Survey in Familial Parkinson Disease Genes Reveals Multiple Independent Copy Number Variation Events in PARK2. Human mutation, 34(8), 1071-1074.

Nuytemans, K., Bademci, G., Inchausti, V., Dressen, A., Kinnamon, D. D., Mehta, A., … & Scott, W. K. (2013). Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology, 80(11), 982-989.

Dumitriu, A., Latourelle, J. C., Hadzi, T. C., Pankratz, N., Garza, D., Miller, J. P., … & Myers, R. H. (2012). Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet, 8(6), e1002794.

Nuytemans K, et al. C9ORF72 repeat expansion is a risk factor for Parkinson Disease. The 62nd Annual Meeting of the American Society of Human Genetics (ASHG), San Francisco, CA, November 6-10, 2012 (Platform presentation).

Bademci, G., M Vance, J., & Wang, L. (2012). Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson’s disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 11(4), 469-481.

Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M. X., Rosado, L., Reilly, M. O., … & Louis, E. (2012). Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study. Neurology, 78(18), 1434-1440.

Pankratz, N., Beecham, G. W., DeStefano, A. L., Dawson, T. M., Doheny, K. F., Factor, S. A., … & Krainc, D. (2012). Meta‐analysis of Parkinson’s Disease: Identification of a novel locus, RIT2. Annals of neurology, 71(3), 370-384.

Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M. M., … & Liu, T. (2012). Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet, 8(3), e1002548.

Cummings, A. C., Lee, S. L., McCauley, J. L., Jiang, L., Crunk, A., McFarland, L. L., … & Scott, W. K. (2011).A Genome‐Wide Linkage Screen in the Amish with Parkinson Disease Points to Chromosome 6. Annals of human genetics, 75(3), 351-358.

Züchner, S., Dallman, J., Wen, R., Beecham, G., Naj, A., Farooq, A., … & Edwards, Y. J. (2011). Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa. The American Journal of Human Genetics, 88(2), 201-206.

Srivastava, A., Tang, M. X., Mejia-Santana, H., Rosado, L., Louis, E. D., Caccappolo, E., … & Nance, M. (2011). The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism & related disorders,17(10), 740-744.

Caccappolo, E., Alcalay, R. N., Mejia-Santana, H., Tang, M. X., Rakitin, B., Rosado, L., … & Nance, M. A. (2011). Neuropsychological profile of Parkin mutation carriers with and without Parkinson Disease: the CORE-PD Study. Journal of the International Neuropsychological Society, 17(01), 91-100.

Hedges, D. J., Guettouche, T., Yang, S., Bademci, G., Diaz, A., Andersen, A., … & Beecham, G. W. (2011). Comparison of three targeted enrichment strategies on the SOLiD sequencing platform. PloS one, 6(4), e18595.

Butler MW, Burt A, Edwards T, Zuchner S, Scott WK, Martin ER, VANCE JM, Wang L. (2011). Vitamin D Receptor Gene Confers Genetic Risks for Parkinson Disease. Ann Hum Genet. 2011 Mar;75(2):201-10.

Edwards, Y. J., Beecham, G. W., Scott, W. K., Khuri, S., Bademci, G., Tekin, D., … & Tsinoremas, N. (2011). Identifying consensus disease pathways in Parkinson’s disease using an integrative systems biology approach. PLoS one, 6(2), e16917.

Hamza, T. H., Chen, H., Hill-Burns, E. M., Rhodes, S. L., Montimurro, J., Kay, D. M., … & Yearout, D. (2011). Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson’s disease modifier gene via interaction with coffee. PLoS Genet, 7(8), e1002237.

Martins, M., Rosa, A., Guedes, L. C., Fonseca, B. V., Gotovac, K., Violante, S., … & Vance, J. M. (2011). Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson’s disease. PloS one, 6(10), e25443.

Alcalay, R. N., Siderowf, A., Ottman, R., Caccappolo, E., Mejia-Santana, H., Tang, M. X., … & Fahn, S. (2011). Olfaction in Parkin heterozygotes and compound heterozygotes The CORE-PD study. Neurology, 76(4), 319-326.

Click here for more publications